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Prophylactic Versus Selective Lidocaine for Early Ventricular
Arrhythmias of Myocardial Infarction
D. GEORGE WYSE, MD, PHD, FACC, JOYCE KELLEN, RN, BN,
ALFRED W. RADEMAKER, PHD
Cot gory . Alberta, Cnnndo
A total of 333 patients arriving within 6 h of the onset of
suspected or proven but uncomplicated myocardial infarc-
tion were randomized to treatment by either the prophy-
lactic or the selective lidocaine strategy . Patients were
monitored for 24 h . The major end points were sustained
ventricular tachyeardia or fibrillation and emergent ad.
verse effects of lidoealne .
There were four episodes of emergent adverse effects of
lidneatne, all in patients treated by the prophylactic strat-
egy (2.4%, p = NS) . There were two episodes of nonagonal,
sustained ventricular tachycardin or fibrillation, both in
patients treated by the selective strategy (1 .2%, p = NS)
.
The difference between major end points was 1
.2% in favor
of the selective strategy (p = NS) . There were significant
differences in lesser ventricular ardgthenias and lesser
Lidocaine is widely used for treatment of early ventricular
arrhythmias of acute myocardial infarction, however, the
most appropriate strategy for administration of the drug is
controversial (1) . The prophylactic strategy is based on the
hypothesis that "warning" arrhythmias do not occur or are
undetected before occurrence of lethal ventricular arrhyth-
mias, or are ultimately found in the vast majority of patients
with myocardial infarction, or both . Practitioners of the
prophylactic strategy cite one clinical trial (2) showing
prevention of early ventricular fibrillation, albeit with no
change in mortality, to support their approach
. That trial is
characterized by I) a high incidence of ventricular fibrillmion
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lidacaine adverse effects but no difference in mortality rate
(selective = 3%, prophylactic = 5%, p = NS)
. Potentially
lethal ventricular arrhythmias occurred only in patients
with myocardial Infarction . Nonlethal but complex ventric-
ular arrhythmias were rare in patients without infarction.
However, toxicity occurred in patients with and without
infarction .
The major conclusion of this study is that there is no
important overall advantage of either strategy for lidocaine
use in such patients . The advantage of one is the risk of the
other
. The strategy used should be selected for Individual
patients, and the use of one strategy for all patients would
seem inappropriate.
(J Am Coll Co,diol 7988;12:507-13)
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in the placebo group in which therapy was withheld until
"persistent ventricular tachycardia or fibrillation" occurred,
and 2) exclusion of all patients started on therapy who did
not have a myocardial infarction.
The selecrtre strategy is based on the hypothesis that
many of the patients more likely to have potentially lethal
ventricular arrhythmias can be identified by "warning"
arrhythmias, Practitioners of the selective strategy support
their approach by citing a number of studies (3) showing
no benefit from the prophylactic strategy and more re-
cent studies (4 .6) showing I) a tow incidence of early
ventricular fibrillation consequent from uncomplicated myo-
cardial infarction, 2) large proportions of patients without
myocardial infarction treated when therapy is very early,
and 3) adverse effects more serious and frequent than
previously reported.
We report here a randomized clinical trial that began on
Oct- 24 . 1979 and terminated on August 20, 1986 after
randomization of 333 patients . Dur trial compares both
anlianhythmic and adverse effects of the prophylactic and
selective strategies .
0735-10971ge1S3 .50
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Methods
Patient selection, Patients were evaluated for the trial
when they presented within 6 h of chest pain diagnosed as
proven or suspected acute myocardial infarction . Proven
myocardial infarction was defined as chest pain plus typical
Q waves and evolutionary ST-T changes in the electrocar-
diogram (ECG) or a serial increase in serum creative kinase
(total or M13 fraction), or both . Patients were excluded if
they were >75 years old, had complex ventricular arrhyth-
mias requiring treatment on arrival, were in advanced heart
failure or shock, had a contraindication to lidocaine such as
persistent sinus bradycardia (<45 bealslmin), liver disease
or allergy, had received antiarrhythmic drugs in the previous
24 h or refused consent . Patients gave written consent, and
this study and its consent form were approved by the Joint
Ethics Committee of the University of Calgary and Foothills
Hospital .
Drug administration. On randomization, drug (placebo or
lidocaine) was administered in a double-blind manner as a
100 mg intravenous loading infusion given over 3 to 5 min,
followed by a 3 mg/min continuous intravenous maintenance
infusion . An identical 100 mg intravenous infusion was
administered .'0 min after the first loading infusion . The
dosage was adjusted on a milligram per kilogram basis for
those patients <50 or >90 kg . These dosages are based on a
pilot study in which serum lidocaine levels were monitored .
The same pre- and postrandomieation data were collected on
all excluded patients between April 1, 1982 and the end of
the trial . Arrhythmia and adverse effect data were not
obtained for the excluded patients .
Arrhythmia monitoring. Arrhythmia monitoring by staff
consisted of bedside and central monitors as previously
described (6) . The patient's ECG was also monitored by
continuous tape recordings with a two channel recorder
(Avionics model 445). These recordings were unavailable to
the coronary care unit staff and their purpose was accurate
arrhythmia quantification . Continuous ECG recordings were
analyzed later by a research nurse who was unaware of the
treatment strategy
.
The sluff unblinded : reerment on detection of canplex
ventricular arrhyrluuius (>5 ventricular premature beats/
mm, couplets, rues, vcn .ricalar lachycardia, multiform ven-
tricular premature beats or R on T phenomenon) . Ventricu-
lar tachycardia was defined as five or more successive
ventricular premature beats with an average RR interval
<_500 ms, and the same F R interval criterion was applied to
ventricular couplets and 'uns . Sustained ventricular tachy-
cardia was defined as tha' lasting '-30 s or requiring trans-
thoracic cardioversion fot hemodynamic collapse . R on T
was defined as a ventricuh r premature beat with an RR/QT
ratio <1 .0 . Multiform was defined as two or more forms of
ventricular premature beats within I h.
After unblinding for are of these r/ytlons, the protocol
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required patients receiving placebo to receive lidocaine in an
open label fashion (selective strategy) . For those patients
already receiving lidocaine on unblinding for oerhythmias
(prophylactic strategy), therapeutic decisions were individ-
ualized by the physician in charge . Other reasons for on-
blinding included major lidocaine toxicity (see the following
section on adverse drug effects), no evidence of infarction,
onset of shock, heart failure or other exclusion criterion,
withdrawal of consent or death. The period of monitoring
was 24 h from the onset of treatment. The two major end
points were I) sustained ventricular tachycardia or fibrilla-
tion that was nonagonal and occurred in the absence of
pulmonary edema, shock, failure of another major organ
system or any other identifiable secondary cause ; and 2)
emergent lidocaine toxicity (see discussion of adverse drug
effects) .
Adverse drug effects. Patients were also monitored for
adverse effects potentially due to lidocaine
(6)
. Symptoms
recorded included confusion, slurred speech, dizziness,
numbness of lips or tongue, double vision or tremor . These
were classified as minor (requiring no alteration of treat-
ment) or major (serious enough to merit unblinding) . The
protocol also permitted unblinding for severe and persistent
nausea and vomiting or persistent bradycardia <45 but >35
beats/min as potential adverse effects of lidocaine. The
occurrence of emergent problems such as seizures, loss of
consciousness, severe and persistent sinus bradycardia
(_<35/min), respiratory arrest or asystole (?5 s) were also
recorded,
Data analysis . Comparison of selective and prophylactic
strategies was done by chi-square analysis, Fisher's exact
test or by unpaired r tests . Standard statistical packages
(SPSS and BMDP) were used for these analyses (7,8) . Large
sample continuity corrected confidence intervals for the
difference in proportions (9) were calculated for the two
major end points . The null hypothesis for _each variable was
rejected when p was <0 .05 .
Results
Comparison of patient groups . A total of 34 prerandomi-
zation and 31 postrandomization clinical variables in addi-
tion to the study end paints were recorded and a selection of
these are presented in Tables I and 2 . With two exceptions,
randomization resulted in matching of the two groups .
Fewer patients with diabetes were randomized to the pro-
phylactic strategy (Table I), and slightly more patients
randomized to the prophylactic strategy had an anterior
infarction (Table 2), Approximately 60% of enrolled patients
ultimately had proven myocardial infarction (Table 2) . The
most common reason for unblinding treatment was distinctly
different in the two groups. In the prophylactic strategy
group it was adverse effects of lidocaine, and in the selective
strategy group it was complex ventricular arrhythmias .
JACC Vu:. 12, Nu . 2_
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Table l . Selected Baseline Characteristics in 333 Patients Before Randomization
All Patients Patients With MI Patients Without MI
Sel
Chamdeeatic a = 165
In
only one instance did a study end point play a role in
death (see discussion of comparison of major study end
points)
. Four of the remaining five deaths in the first 24 h
were due to cardiogenic shock or myocardial rupture and
one was due to severe dissection of the aortic root. There
were seven additional deaths after the first 24 h . The major
(dale 75x3
Previous MI 28 x 3
Hypencnstan 33 x 4
Diabetes isx3
Smoker 51 1 4
Role, 17x3
S J 6x2
Qwaves 1503
Increased heart sin
8 ,- 2
DeflnileMI at entry 30'-4
On beta-bleeker 19' 3
On streplukinase 12 2 3
Onset to anivol (mint 133 *_ 6
On- 1. mrdomiaatiou (au.) 357 2 10
Age lye) 57 x 1
Serum CK(Uditcr) 134-19
Serum pouusium lmmoliilerl 4 1 'nut
'p < 0
.05 selective vs. prophyl0cdc
; tp 10
.10 seteaile no, p
rophylccric
. C
K =creative h/eon, ; MI
-
myocardial infarction; Pro = prophylaetic lidmaine
strategy ; S, = thud hour sound; Set = selective lidoeaine strategy.
Table 2. Selected Post randomization Characteristics End Points in 333 Patients
cause
of
death included pump failure (congestive heart
failure, cardiugenic shock or myocardial rupture) in six of
the seven, and was aortic dissection in the remaining case.
Thus, there were two deaths in patients without myocardial
ioL:c;ion and both of these were due to acute aortic dissec-
tion . Agoncl . sustained ventricular tachycardia or fibrillation
'p < 0,05 selective vs- prophylactic : to < 11.111 veieu ate vs- prophylactic . CCLI = c,,rorary care unit: other abbreviations as in Table 1 .
All Potwms Patients With Ml Patients Without MI
So) Pro Set Pro Sot Pro
Chureclerislie
n-14$ a=168 n-91 n=100 a=75 n=68
Pcrcenl x SE
Termination <24 h 46 x 4 0 x 4 61x5 46x51 29x5 32*_6
Tearaitrorad fear
Lidocaine lordly x 1 17 *_ 1' 2 21 17x4' 1 `1 16x4-
Veotricuier mall 30 4 11 2* 49 '_5 16'-4' 8x3 3x'
Proven 611 55 4 60 x 4 100 100 a o
Ails nor 31 *_ 5 49 --- 5' - -
Heart failure 13 x 3 I I x 2 19r4 15"- 4 523 6x3
Hospital monalily 3
x
1 5 x 2 4 2 7x3 121 1 t I
M". . ± SE
Peak CK (Ullilerl 677 x 71 773 x ill 1142 x 107 1174 x 94 136 x 29 207 x 56
Treatment duration (h) 17,5 x 0.7
18±1'
0.0 11 .4x1 .11
16
.3=1 .0 21 .2x0.7
20
.6±0 .7
Days in CCU 3 .9 x 6
.3 3
.9 x IL l 4 .5x0
.5 4
.4x0.2
3 .1x0.2 3.2x0
.2
Da
ys
in hospital
10
.8 x 0
.6 11 .3 x 0 .6 11 .5x0 .8 13 .0 *_0,8 9.5x0.7 8 .9!0
.8
Set
Pro
n = 7$ e = 68
68±5 74 *_5
35 x 6 29 x 6
31 v 5 -
17_4 '6x
e.
30
49 0 6 57 - 6
16x9 18x5
517 7x1
8x3 1204
II x 4 7 x 3
3-2 3x2
20 x 5 16 x 4
1 x 1
1 ! 1
131 x 10 137 - 10
374 ! 14 401 *_ 16
57 0 1 565: 1
90-12 79-9
4.2 = 0.05 4.2 x 0.06
Pro
n = 168
Set
n = 90
Pro
n = 100
Percent _ SE
77x3 81x4 8004
25 x 3 23 x 4 22 x 4
28 x 3 3- 5 27 x 4
8x2' 18x4 1003
56 x 4 52 *- S 56' 5
18x3 18_4 18!4
8x 2
7x1
9x3
19-_3 21 . 4 2324
8 x 2 6 3
8 x 3
37'_4 52 5 60x5
13 x 3 18 *- 4 10 x 3
12 x 3 20 0 4 19 2 4
Moan x SE
129 e, 11, x 8 124 x 8
352 x 10 343 - 15 318 x 12
56 x 1 57 x 1 56 s: 1
143x21 171±34 IRS 35
4 .1 x o .IW 4 .1 ± 0 .a5 4.1 x 0.05
5
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INCIDENCE RATE (%)
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Figure Figure L Comparison of the incidence late of the major end points
in the two treatment strategies of this study . Each point is the
percent incidence and the borizonlat fines indicate the 95% confi-
dence intervals. A point to the right of zero suggests the selective
strategy is better then the prophylactic strategy, A point to the left
of zero suggests the prophylactic strategy is better than !he selective
strategy . Not = difference between toxicity and VTIVF ; Toxicity =
emergent adverse effects of lid ocaine : VT/VF - sustained venoiru-
lar tachycardia or fibrillationn
occurred in 5 of the 10 patients wish death due to pump
failure, and in I patient who died of aortic dissection ; all 6
patients were already receiving lidocaine at the time .
Comparison of major study end points, The differences
between the two treatment groups with respect to the major
end points of this study are presented in Figure l . There
were (oo episodes of emergent ad-se effects potentially
attributable to lidocaine (toxicity), and all occurred in pa-
tients randomized to the prophylactic strategy (p = 0 .12) . A
64 year old man receiving a beta-adrenergic blocker devel-
oped a heart rate of 33 beats/min and 30 s of apnea after 18
h of treatment ; he responded to intravenous administration
of atropine . Two hours earlier he had minor symptoms of
nausea and slurred speech (code not broken). A 70 year old
man with an anteroseptal infarction had a heart rate of 40
heats/min followed immediately by 6 s of asystole and a
heart rate of 25 beats/min 75 min after randomization . He
was unconscious but responded promptly to chest compres-
sion and intravenous atropine . A 59 year old woman had a
seizure during administration of the second loading infusion .
Treatment was immediately discontinued, but 24 h later she
had a second seizure ; she had never previously had a
seizure . None of these three patients died . The fourth
patient, a 65 year old man with anterelateral infarction,
became unconscious shortly after the first loading infusion ;
this event was quickly followed by a seizure, apnea and
asystole
; resuscitation was unsuccessful
. Subsequent review
showed a discrepancy in the treatment drug containers
indicating that the patient had been given a I g container of
lidocaine rather than 100 mg.
There
were two episodes
of etrstoined renoirular Jnehy-
cardia and fibrillation (Fig . 1) in the absence of arts' cause
other
those
art ancurnplicored myocardial iufarclirrv. Both of
these occurred in patients randomized to the selective strat-
egy (p = 0.50) . A 44 year old man with an anterior myocar-
dial infarction randomized within 116 min of the onset of
b eo
4o
20
a0
40
za
Figure 2. Comparison of the incidence rate (percent of patients) of
multiform and successive forms of ventricular premature beats (see
Methods) in the two treatment strategies of this study . Vertical lines
on the topof the bars are ± SE . Numbers at the bottom of each bar
are those used to calculate incidence rate
. MI = myocardial infarc-
lion ; VT = ventricular tachycardia .
pain developed rapid ventricular tachycardia degenerating
into fibrillation within 9 min of institution of therapy
; cardio-
version was successful
. A 50 year old man with inferior
myocardial infarction was randomized within 120 min of
arrival and 270 min of the onset of main . Forty minutes later
he had complex ventricular arrhythmias, and 2 min after that
developed sustained monoform ventricular tachycardia at a
rate of 150 beats/min requiring cardioversion . Neither of
these patients died .
Thus, the overall percent incidence of major events in
favor of one strategy and its 95% confidence interval is
presented as the bottom point
("Net')
in Figure I and was
1 .2% in favor of the selective. strategy (p = 0.68) .
Lesser ventricular arrhythmias . The effects of the two
treatment strategies on incidence of lesser ventricular
arhythmius are presented in Figure 2 . Similar results were
obtained when ventricular arrhythmias were tabulated for
each hour of monitoring. The incidence of frequent ventri-
cular premature heats and R on T phenomenon was not
significantly different in patients with myocardial infarction
randomized to either strategy (ant illustrated) . Complex
ventricular arrhythmias were uncommon in patients without
proven myocardial infarction . Fifty patients (30%) random-
ized to the selective strategy had initial treatment unblinded
N
- ea,oo
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20
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Figure 3. Comparison of the incidence rate (percent of patients) of
minor and major adverse carets possibly attributable m lidocaine
(see Methods) in the two treatment strategies of this study- Symbols
and abbreviations as in Figure 2 .
for complex ventricular arrhythmias and 47 of these were
started on lidocaine therapy . The remaining three had devel-
oped concomitant contraindications to lidocaine therapy,
Eighteen patients (l1%) randomized to the prophylactic
strategy had initial therapy unblinded for complex ventricu-
lar arrhythmias . They were treated as follows : nine with no
change, five with additional lidocaine, three with continua-
tion of lidocaine and a second drug added and one with
discontinuation of lidocaine .
Lesser adverse drug effects. The incidence of minor and
major adverse effects potentially attributable to lidocaine are
presented in Figure 3. Unlike arrhythmias, adverse drug
effects occurred in patients with and without a proven
myocardial infarction. Twenty-eight patients (17%) random-
ized to the prophylactic strategy had their initial treatment
unblinded for adverse effects of lidocaine. They were treated
as follows: I with no alteration, 3 with reduced dosage and
24 with discontinuation of the drug. The three patients Q%)
randomized to the selective treatment strategy whose initial
treatment (that is, placebo ; was unblinded for major adverse
effects had the following symptoms
: two had nausea and
vomiting and one had sinus bradycardia . A breakdown ofthe
type of adverse effect according to whether or not the patient
had a proven myocardial infarction is not presented but was
similar to that of a previous report
(6)
.
Comparison of study patients to selected groups of excluded
patients. Data were available on a total of 1,044 excluded
patients . The major reasons for exctusion were as follows : I )
WYSE ET AL . sit
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>6 h from the onset of pain without another exclusion, 29% ;
2) missed, 14% ; 3) >6 h from the onset of pain with another
exclusion, 11%; 4) receiving lidocaine, 10% ; 5) >75 years
old, 8%; 6) receiving another antiarrhythmie drug, 4%; 7) no
consent, 4%
; 8) all other single exclusions, 8% ; and 9)
multiple exclusions, 20%
.
1n Tables 3 and 4, pre- and postrandomiza :ion variables
for the patients who were missed or did net consent (185
patients) and for those excluded because they were already
receiving lidocaine (102 patients) are presented and com-
pared with those of the 333 randomized patients. For ex-
cluded patients, the time from "onset to randomization"
was that
from onset to arrival in the coronary care unit
where the study patients were randomized .
Another difference in pre-and postrandomizetiun
varia-
bles
is that 19 s 4% of the patients receiving lidocaine
underwent cardioversion, compared with 2 ± 1% of random-
ized patients and I t 1% of patients missed or not consent-
ing (p < 0.05). A substantial portion (18 of 22) of these
cardioversions were for sustained ventricular tachyeardia or
fibrillation, which occurred before arrival (12 of 18) or in the
emergency room (6 of I8) . All 12 out-of-hospital patients and
3 of 6 patients in the emergency room were not started on
lidocaine therapy until after cardioversion-The four remain-
Table 3 . Selected Baseline Patient Characteristics of Randomized
and Two Subgroups of Excluded Patients
Exdaded F bents
'p
< 0 .115 rcedenired vemus excluded subgroup
.
Fp < 0 .10 mndnmired
secsuc
-Wad
subgroup. Abbreviations as in Tables 1 and 2-
Cbamelenstic
Randomized
Patients
(n - 333)
Missed or
No Consent
In = 185)
Cn
Lidrcaine
In
= ID2)
Percent - SE
Made 7632 7123 69_5
Previous 611 27 x 2 38 x 4'
24 x 4
Hyproemion 30
3
3
19 x 4'
43'- 5'
niahetes
1332 16 s3 10!3
Smoker 54 * 3 51 ¢ 4 43 3 In
Rates 1772 13x2 2134
5,
7x1 10_2 823
0 oases 1752
19x3
26x41
Increased I--art size 2 x 1 11 3 2 21 3 4
Definite MI u1 entry 31
x 3
34'_ 3 48 _ 5-
0, beta blacker 16 - 2 24 .0 3' 22 n 4
Or.s!leptokinarr 12 x 2 I *_ I' 0'
Mean x SE
Onset In arrival (min) 131 x 5 167 x 10' 190 0 37-
On-t randomization (min) 285 e. 6 388 x 22' 417 ± 72'
Age (yr) 57 7 I 59 0 1' 61 *_ 1-
Semis CK (Ulliter) 138'_ 14 166- 20 206 x 54
Serum potassium 4,1 '_ 0.03 41 3 0 .05 4 .1 x 0 .10
Immrlherl
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Table 4. Selected Post-Admission Patient Characteristics of
Randomized and Two Subgroups of Excluded Patients
-p < 0 .05 randomized	luded ,'hrsrsp. Abbrevialbns a, in Table,
I and 2.
ing cardioversions occurred later during hospitalization . One
was performed for atrial fibrillation, two were performed
during agonal ventricular fibrillation in patients already
receiving lidocaine and one was performed far cardiac arrest
in a patient not receiving antiarrhythmic drugs .
Discussion
Comparison of patient groups. The randomization proc-
ess resulted in two very comparable groups of patients
receiving the prophylactic and selective strategies . Given
that 65 clinical variables were examined in addition to the
study end points, one could expect a p value of <0
.05 to
occur by chance alone in 3 of these variables . It is unlikely
that the two differences found affect the findings of this
study . Of the two differences found
. the site of infarction is
potentially important
. With respect to the major end points,
sustained ventricular tachycardia or fibrillation occurred
once each in patients with anterior or inferior infarction, and
emergent adverse effects of lidocaine were observed in two
patients with anterior infarction and two without infarction
.
We also analyzed for differences in site of infarction between
patients with and without lesser arrhythmias and adverse
effects of lidocaine and found none . Finally, site of infarction
was obtained from the initial admission ECG, which results
in imprecise specification of infarction location
.
Comparison of major study end points . The prophylactic
strategy resulted in a small (2 to 3%) excess of emergent
lidocaine toxicity and the selective strategy resulted in a
small (1 to 2%) excess of sustained ventricular tachycardia
or fibrillation. There was no difference in mortality. A study
with sufficient power to show a statistical difference between
the two approaches with respect to the major end points
would require that a total of up to 13,000 patients be enrolled
and randomized . In our view, such a study is unwarranted
JACC Vol . 12, Na . 2
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because any difference demonstrated would have trivial
clinical importance.
On the basis of analysis of the patients excluded from our
study, we estimated that these results can be generalized to
a substantial number of patients . There are no important
differences between the study patients and the patients who
were excluded because they were missed or did not give
consent . Thus, the study results can be generalized to all of
these. They can also be generalized to many of those
excluded because they were already receiving lidocaine,
because approximately half of these patients had lidocaine
therapy started for "prophylaxis" or noncomplex ventricu-
lar arrhythmias .
The present study results are different from those of Lie
et al. (2), the lone study suggesting a benefit of the prophy-
lactic strategy . This may be partly because our study in-
cluded more patients with a lower risk of sustained ventri-
cular tachycardialfibrillation or partly because we assessed
lidocaine toxicity more carefully . The difference is probably
mostly due to the fact that in the present study treatment
with lidocaine was mandated in patients receiving placebo
when complex ventricular arrhythmias were detected,
whereas in the study of Lie et al . (2) patients receiving
placebo were not treated unless "persistent" ventricular
lachycardia or fibrillation occurred . Thus, the two studies
are not comparable .
Comparison of lesser study end points. As previously
pointed out by us
(6), lesser adverse effects of lidocaine are
common when the prophylactic strategy is used . Impor-
tantly, and unlike ventricular arrhythmias, lesser adverse
effects (like emergent adverse effects) of lidocaine occur at
least as frequently in patients without myocardial infarction
as they do in patients with infarction .
Complex ventricular arrlrydunias are imperfect for selec-
tion of patients with myocardial infarction at risk of sus-
tained ventricular tachycardia or fibrillation (10). However,
complex ventricular arrhythmias were infrequent in the
patients who did not have a myocardial infarction . This
finding is important because patients with chest pain but
without myocardial infarction have an extremely low risk (0
of 143 patients in this study) of sustained ventricular tachy-
cardia or fibrillation whereas they are at equal risk for
adverse effects of lidocaine.
Potential limitations of study . A lower dose of lidocaine,
particularly for the second loading infusion, may have re-
sulted in fewer adverse effects in those treated with the
prophylactic strategy
. Conversely, however, lowering the
dosages may have resulted in more ventricular tachycardia
or fibrillation with the prophylactic strategy . Fewer serious
adverse effects might hove occurred if the infusion rate had
been lowered at the first symptom of adverse effects or if
plasma lidocaine levels had been used to monitor therapy
.
Obviously, the latter is not possible in a double blind trial,
but in addition, plasma lidocaine levels are not commonly
Excluded Patients
Charaolerlslic
Randomized Missed nr
Patients No csent
In =333) fii 711851
On
Lidocaine
(n=10^-1
Percent ± SE
Proved MI 57 ± 3 62 x 4 76 ± 4-
11- failure 12 2 17 ! 3 28 x 4'
Hospital
-.lily
4 x I 5 *_ 2 13 x 3'
Mean x SE
Peak CK 739 - 51
752 x 73 1320
x
124'
Days is CCU 3 .9'02
3
.7'_0.2
4
.7x0
.3'
Days in hosplal
11
.1 : 0.4
11 .1 m 0.7 13 .9! 0.9-
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available as a "slat" procedure nor are they well correlated
with adverse effects (6) . It should be noted that minor
adverse effects of lidocaine are nondescript ; 19% of the
patients with myocardial infarction receiving placebo in the
present study were thought to have minor adverse effects of
lidocaine ; thus their infusion rate would have been inappro-
priately lowered if this indicator had been used, perhaps
resulting in more ventricular arrhythmias .
The present results and conclusions are unaltered when
analysis is limited to the data from those patients with
definite myocardial infarction . However, exclusion of pa-
tients without myocardial infarction in whom treatment was
started is contrary to the principle of "intention to treat" and
is a major weakness of the study of Lie et al . (2). Indeed, in
the present study, treatment was discontinued as soon as
myocardial infarction was excluded, which even optimally
took 12 to 16 h . Finally, using the prophylactic strategy only
for definite myocardial infarction in Ibis study would have
meant not treating about 45% of those at risk for ventricular
tachycardia or fibrillation (Table 1) .
Even earlier treatment may be core e,Qecrive . Whereas
this statement may be true in the case of a definite myocar-
dial infarction, there are data (5) to show clearly that when
this decision is made very early, without benefit of confir-
matory tests, the proportion of patients without infarction
increases sharply and results in a similar trade-off between
antiarrhythmic effectiveness and adverse effects such as
those demonstrated in the present trial .
Finally, even if a proponent of the prophylactic strategy
rationalizes away all the episodes of emergent adverse
effects in the present study (the ultimate in bias and clearly
improbable), there is still no significant difference between
groups in the incidence of ventricular tachycardia or fibril-
lation (p = 0 .50). Sufficient power to show even complete
effectiveness of the prophylactic strategy (unlikely) for an
event with 1 .2% frequency in the selective strategy would
require randomization of 13,000 patients . On this basis and
the basis of no observed difference in mortality, the wisdom
of one strategy for all patients must be questioned,
These results cannot be generalized to more aggressive
management of patients presenting early during acute myo-
cardial infarction because only approximately 20% of our
patients with infarction received thrombolylic therapy . A
randomized trial of lidocaine in such patients may be war-
ranted .
Clinical relevance. The present trial, like two other recent
trials (4,5), suggests that adverse effects of lidocaine used
prophylactically may offset any benefits, particularly when
higher proportions of patients without myocardial infarction
are included in this approach ( •; I. The dilemma created by
this finding is that the incidence of ventricular fibrillation is
greatest early in the course of myocardial infarction (10,11),
WYSE ET AL .
	
513
PROPHYLACTIC VERSUS SELECTIVE LIDOCAINE
which is precisely the time when the diagnosis is most
uncertain.
The strategy one selects should be determined individu-
ally by the clinical circumstances . The prophylactic strategy
may be preferable early during the course of a definite
myocardial infarction, particularly when rhythm monitoring
and capability for resuscitation are uncertain . When the
prophylactic strategy is used, lidocaine should be discontin-
ued as soon as possible and in any event after no more than
12 to 24 h . The selective strategy may be preferable later
during the course of a definite myocardial infarction, partic-
ularly when rhythm monitoring and resuscitation capability
are certain and most particularly when the diagnosis of
myocardial infarction is in doubt .
The us,ivancc aid cooperation ore large number olpeople were necessary to
complete hi, study . We am grateful to the physicians of the Foathilts
Hospital who allowed us to study their patients . The study could not have
been done without the help of the house staff and nurses who worked in the
coronary care unit . Aetta Canada supplied the lidocaine used in this study .
The rollowing individuals made special mntributuns to completion of the
study : Sharer Capot . RN, Rahen Sevick. MD . Elaine Scott, BSc, Dadene
Abbott . RN, MSc, Sheila Ffvelle, IN, Penn Kletnsttver, MSc, Lynne Fator .
RN. Virg,l Dais, D Phann, David Merry, MD and Dan Soboleski, MD .
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